Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ligand Binding and Linkage00:49

Ligand Binding and Linkage

4.9K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.9K
Ligand Binding Sites02:40

Ligand Binding Sites

13.2K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
13.2K
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

13.4K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
13.4K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

869
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
869

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is it time to implement a hemorheology passport in sickle cell disease?

Blood cells, molecules & diseases·2026
Same author

Rational design of Pickering emulsion-templated silica capsules loaded with ionic liquids: tailoring intrinsic textural properties <i>via</i> interfacial sol-gel kinetics.

Nanoscale·2026
Same author

Exploring the impact of safe patient handling and mobility program compliance on patient handling injury rates.

Journal of safety research·2026
Same author

A Mixed-methods Evaluation of Attitudes and Perceptions of Multispecialty Learners Undertaking a Hybrid Research Methodology Course in Low-resourced Settings.

The annals of African surgery·2026
Same author

Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer's disease.

Nature aging·2026
Same author

Should we longitudinally monitor blood viscosity in patients with sickle cell anemia?

Blood cells, molecules & diseases·2026

Related Experiment Video

Updated: Sep 10, 2025

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
13:51

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay

Published on: November 11, 2018

10.0K

Solution-based studies on the contact between the complement receptor 3 ligand-binding domain and simvastatin.

Morten Hulbæk Fog1, Violaine Hubert2, Corinne Sanglar3

  • 1Biophysical Immunology Laboratory, Dept. of Biomedicine, Aarhus University, DK-8000 Aarhus C, Denmark.

Biochimica Et Biophysica Acta. Proteins and Proteomics
|August 20, 2025
PubMed
Summary

Simvastatin

Keywords:
AntagonismComplement receptor 3I domainIntegrinSimvastatinStroke

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.5K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Related Experiment Videos

Last Updated: Sep 10, 2025

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
13:51

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay

Published on: November 11, 2018

10.0K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.5K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Area of Science:

  • Pharmacology
  • Immunology
  • Biochemistry

Background:

  • Simvastatin, a cholesterol-lowering drug, exhibits anti-inflammatory effects by targeting CD18 integrins.
  • Lymphocyte-associated antigen (LFA)-1 and complement receptor 3 (CR3) are key CD18 integrins involved in immune responses.
  • Simvastatin's inhibitory mechanisms on LFA-1 and CR3 have been proposed but require further elucidation.

Purpose of the Study:

  • To investigate the distinct mechanisms by which simvastatin inhibits LFA-1 and CR3.
  • To compare the inhibitory potencies of simvastatin's lactone (simvastatin-lac) and carboxylate (simvastatin-carbox) forms on CR3.
  • To evaluate the functional consequences of simvastatin-carbox inhibition on CR3-mediated functions and in an in vivo stroke model.

Main Methods:

  • Affinity measurements (K_D) of simvastatin-carbox for the αM integrin I (αMI) domain.
  • Inhibition assays of CR3 binding to iC3b.
  • Assessment of simvastatin's neuroprotective and anti-inflammatory effects in a middle cerebral artery occlusion (MCAO) animal model.

Main Results:

  • Simvastatin-carbox showed weak affinity (K_D ≈ 650 μM) for the αMI domain, significantly lower than simvastatin-lac's inhibitory concentration (50 μM).
  • Simvastatin-carbox did not inhibit CR3 binding to iC3b and lacked efficacy in the MCAO stroke model.
  • Simvastatin-lac effectively inhibits both LFA-1 and CR3 through distinct allosteric and potentially ternary complex-mediated mechanisms.

Conclusions:

  • Simvastatin-lac antagonizes LFA-1 via allosteric binding to the αI domain.
  • Simvastatin-lac inhibits CR3 through a distinct mechanism involving a ternary complex formation, with the carboxylate form showing weak affinity.
  • The anti-inflammatory and neuroprotective effects observed in previous studies are likely attributable to simvastatin-lac, not simvastatin-carbox.